Elm Street Ventures

Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug capable of delivering a disease-modifying approach and preserving cognition in patients.

Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and it will greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.

Artizan Biosciences provides pharmaceutical drug development services, namely, the development of small molecule drugs for use in humans. The Durham-based biotech company declined to disclose its intended use of the proceeds from this offering, as well as its current revenue range.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.

EvolveImmune Therapeutics develops an immunobiological platform that delivers both sustained immune activation and tumor cell targeting in a single agent. Through integrated signaling, EVs first in category biologics directly target tumor cells and provide potent, tissue-localized amplification of cytokine secretion at the tumor site to maximize tumor killing. The company's biotherapeutics are engineered to overcome the limitations of conventional CD3 bispecific and other immune therapies to offer a better future for our patients in need, by maximizing therapeutic benefit and minimizing toxicity.

Zid is an e-commerce in a box - solution that any retailer can use to start their eRetail. Zid helps them to build their own eStores (with their own name and identity) and integrates them with the supply chain players to enable them to manage and with ease. The company aims to enable the retail sector to enter the world of electronic retail in an easy and professional. Zid was founded in 2017 and based in Riyadh, Ar Riyad, Saudi Arabia.

Artizan Biosciences provides pharmaceutical drug development services, namely, the development of small molecule drugs for use in humans. The Durham-based biotech company declined to disclose its intended use of the proceeds from this offering, as well as its current revenue range.

Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells to selectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed.

Saphlux provides the industry-first QD in chip micro-LED solutions. The company designs and manufactures micro-LED chips and micro-display modules for display applications. The current products include the NPQD R1 chip for public information display and the NPQD T1 micro-display for AR glasses. The company operates globally in the US, China, and Japan.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

SeeClickFix provides tools for residents and governments to communicate for all sizes, populations, and budgets. The company empowers citizens, community organizations, and governments to care for and improve their neighborhoods by providing technology tools that promote civic engagement and government transparency. They focused reports allow officials at all levels to evaluate public service performance, plan for improvements, and have the facts necessary to make data-driven decisions. SeeClickFix was established in 2008 and is based in New Haven, Connecticut, United States.

Device42 develops a discovery and dependency mapping platform designed to identify, map, and optimize infrastructure and applications across data centers and the cloud. The company's software provides IT operations, compliance and auditing, migration and modernization, IT asset management, dependency mapping, and other services, allowing clients to effectively operate hybrid IT, complete cloud migrations, and fulfill internal and external compliance requirements.

Device42 develops a discovery and dependency mapping platform designed to identify, map, and optimize infrastructure and applications across data centers and the cloud. The company's software provides IT operations, compliance and auditing, migration and modernization, IT asset management, dependency mapping, and other services, allowing clients to effectively operate hybrid IT, complete cloud migrations, and fulfill internal and external compliance requirements.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

Desmos.com provides the first platform-agnostic software for building and sharing rich educational content, bridging the gap between different classrooms, and between the classroom and the home.

Accelerated Orthopedic Technologies, Inc. provides instruments to treat articular cartilage defects with custom sizes, shapes, and matching topography. The company was formerly known as Advanced Orthopedic Technologies, Inc. and changed its name to Accelerated Orthopedic Technologies, Inc. in February 2010. Accelerated Orthopedic Technologies, Inc. was incorporated in 2009 and is based in Guilford, Connecticut.

Metagenomix is an early-stage biotechnology company developing novel methods of screening microbes for pharmacologically active compounds. Among the indications under investigation are cancer, inflammation and infectious diseases including fungal infections and malaria. The technology also has applications in agriculture.

Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells to selectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed.

ShareGrove hosts private online conversations that are media-rich, fluid and dynamic. ShareGrove makes it easy to select friends from Facebook (and other networks), and to engage them in real time, or over time, through a single Web interface. Integrated Web search (from Google, Amazon and Yelp), along with inline presentation of media, add richness and expression to ShareGrove conversations, while also generating revenues through affiliate programs.

Retail Optimization Inc. provides predictive macro optimization analytics to determine the most profitable levels of product selection, category space and inventory investment while enhancing the shopping experience for consumers.

Affomix has proprietary technology for rapid, automated, high-throughput selection of human monoclonal antibodies (mAbs). Their mission is to commercialize proprietary mAbs, mAb microarrays and mAb libraries for research, drug discovery, diagnostic and therapeutic applications, with a particular focus on the use of their mAbs for sensitive and accurate measurement of very large numbers of proteins in biological samples.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.